Guangdong Lifestrong Pharmacy Co., Ltd. (SHE:301111)
China · Delayed Price · Currency is CNY 19.90
+0.26 (1.32%)
Apr 30, 2026, 3:04 PM CST
SHE:301111 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 310.01 | 314.64 | 274.19 | 292.15 | 283.29 | 349.44 |
Other Revenue | - | - | 4.45 | 0.25 | 0.05 | 0.35 |
| 310.01 | 314.64 | 278.64 | 292.4 | 283.34 | 349.79 | |
Revenue Growth (YoY) | 11.41% | 12.92% | -4.71% | 3.20% | -19.00% | 2.59% |
Cost of Revenue | 128.37 | 123.78 | 89 | 94.55 | 92.74 | 107.53 |
Gross Profit | 181.64 | 190.86 | 189.64 | 197.85 | 190.6 | 242.26 |
Selling, General & Admin | 186.85 | 197 | 188.54 | 164.31 | 155.88 | 165.38 |
Research & Development | 8.63 | 8.49 | 8.41 | 8.44 | 9.16 | 10.87 |
Other Operating Expenses | 3.54 | 3.42 | 3.03 | -0.62 | 1.72 | 4.71 |
Operating Expenses | 199.02 | 208.91 | 198.36 | 173.39 | 166.77 | 181.75 |
Operating Income | -17.38 | -18.05 | -8.71 | 24.46 | 23.83 | 60.51 |
Interest Expense | - | - | -2.46 | -0.37 | -0.03 | -0.06 |
Interest & Investment Income | 12.63 | 12.75 | 12.45 | 14.6 | 14.25 | 4.03 |
Other Non Operating Income (Expenses) | -0.31 | -0.85 | -1.93 | -1.01 | -0.03 | -0.04 |
EBT Excluding Unusual Items | -5.06 | -6.15 | -0.66 | 37.68 | 38.03 | 64.44 |
Gain (Loss) on Sale of Investments | 0.58 | 0.52 | 1.67 | 2.78 | 2.93 | 1.55 |
Gain (Loss) on Sale of Assets | 0.62 | - | - | - | -0.33 | -0.01 |
Asset Writedown | -6.08 | -4.12 | -1.02 | -3.8 | -8.4 | -5.69 |
Other Unusual Items | - | - | -0.14 | 0.63 | 2.52 | 6.44 |
Pretax Income | -9.94 | -9.76 | -0.14 | 37.29 | 34.75 | 66.72 |
Income Tax Expense | -1.3 | -0.63 | -1.38 | 4.76 | 1.33 | 9.54 |
Earnings From Continuing Operations | -8.64 | -9.13 | 1.24 | 32.53 | 33.42 | 57.18 |
Minority Interest in Earnings | 4.28 | 4.64 | 2.92 | 0.97 | 0 | - |
Net Income | -4.35 | -4.49 | 4.16 | 33.5 | 33.42 | 57.18 |
Net Income to Common | -4.35 | -4.49 | 4.16 | 33.5 | 33.42 | 57.18 |
Net Income Growth | - | - | -87.58% | 0.25% | -41.56% | -8.54% |
Shares Outstanding (Basic) | 150 | 150 | 139 | 160 | 159 | 119 |
Shares Outstanding (Diluted) | 150 | 150 | 139 | 160 | 159 | 119 |
Shares Change (YoY) | 9.27% | 7.83% | -13.02% | 0.25% | 33.59% | -0.92% |
EPS (Basic) | -0.03 | -0.03 | 0.03 | 0.21 | 0.21 | 0.48 |
EPS (Diluted) | -0.03 | -0.03 | 0.03 | 0.21 | 0.21 | 0.48 |
EPS Growth | - | - | -85.71% | - | -56.25% | -7.69% |
Free Cash Flow | 6.55 | 0.8 | -34.69 | -51.41 | 64.34 | 68.54 |
Free Cash Flow Per Share | 0.04 | 0.01 | -0.25 | -0.32 | 0.40 | 0.57 |
Dividend Per Share | - | - | 0.050 | 0.100 | 0.100 | 0.160 |
Dividend Growth | - | - | -50.00% | - | -37.50% | - |
Gross Margin | 58.59% | 60.66% | 68.06% | 67.66% | 67.27% | 69.26% |
Operating Margin | -5.61% | -5.74% | -3.13% | 8.37% | 8.41% | 17.30% |
Profit Margin | -1.40% | -1.43% | 1.49% | 11.46% | 11.79% | 16.35% |
Free Cash Flow Margin | 2.11% | 0.26% | -12.45% | -17.58% | 22.71% | 19.59% |
EBITDA | -6.86 | -7.49 | 2 | 35.21 | 35.14 | 74.6 |
EBITDA Margin | -2.21% | -2.38% | 0.72% | 12.04% | 12.40% | 21.33% |
D&A For EBITDA | 10.52 | 10.56 | 10.71 | 10.75 | 11.31 | 14.1 |
EBIT | -17.38 | -18.05 | -8.71 | 24.46 | 23.83 | 60.51 |
EBIT Margin | -5.61% | -5.74% | -3.13% | 8.37% | 8.41% | 17.30% |
Effective Tax Rate | - | - | - | 12.76% | 3.83% | 14.30% |
Revenue as Reported | - | - | 278.64 | 292.4 | 283.34 | 349.79 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.